Literature DB >> 12957219

Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover.

N A Darmani1, J J Janoyan, N Kumar, J L Crim.   

Abstract

Large doses (10-40 mg/kg) of the selective cannabinoid CB(1) receptor antagonist, SR 141716A, produce the head-twitch response (HTR) and scratching in rodents and vomiting in the least shrew (Cryptotis parva). Agents that increase brain serotonin (5-HT) levels induce the HTR in rodents, whereas enhancements in either brain 5-HT or dopamine concentrations can lead to production of emesis in vomiting species. The present study was undertaken to demonstrate whether large doses of SR 141716A can (1) induce the HTR and scratching in the least shrew and (2) cause concurrent biochemical changes in brain 5-HT and dopamine concentrations. SR 141716A (0, 1, 5, 10, 20 and 40 mg/kg i.p.) administration induced the HTR, scratching and vomiting. The HTR effect was bell shaped with a maximum frequency occurring at the 20 mg/kg SR 141716A dose, whereas the scratching and vomiting behaviors displayed dose-dependent effects. The selective 5-HT(2A/C) receptor antagonist, SR 46349B (0, 0.1, 0.25, 1, 3 and 6 mg/kg i.p.), differentially attenuated all SR 141716A (20 mg/kg)-induced behaviors because the HTR was relatively more potently and completely blocked. In the shrew forebrain, SR 141716A (20 and 40 mg/kg ip) caused dose- and time-dependent increases in the levels of 5-HT and dopamine and the concentrations of their major metabolites [5-hydroxyindole acetic acid (5-HIAA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanilic acid (HVA)] and the turnover of both monoamines. Although the effects of SR 141716A on brainstem concentrations of both monoamines and their metabolites were not always consistent, the CB(1) antagonist did increase the turnover of both 5-HT and dopamine. The present findings suggest that the mechanism and the neurochemical substrate for SR 141716A-induced HTR and scratching behaviors is enhancement of 5-HT release, whereas increased release of 5-HT and dopamine probably contributes to the production of emesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957219     DOI: 10.1016/s0091-3057(03)00150-3

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  30 in total

Review 1.  Involvement of cannabinoid receptors in gut motility and visceral perception.

Authors:  Pamela J Hornby; Stephen M Prouty
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

2.  Cannabinoids Stimulate the TRP Channel-Dependent Release of Both Serotonin and Dopamine to Modulate Behavior in C. elegans.

Authors:  Mitchell Oakes; Wen Jing Law; Richard Komuniecki
Journal:  J Neurosci       Date:  2019-03-18       Impact factor: 6.167

3.  CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action.

Authors:  Joel E Schlosburg; Scott T O'Neal; Daniel H Conrad; Aron H Lichtman
Journal:  Psychopharmacology (Berl)       Date:  2011-02-22       Impact factor: 4.530

Review 4.  Atypical antipsychotic-induced weight gain: insights into mechanisms of action.

Authors:  James L Roerig; Kristine J Steffen; James E Mitchell
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 5.  Regulation of nausea and vomiting by cannabinoids.

Authors:  Linda A Parker; Erin M Rock; Cheryl L Limebeer
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 6.  Modulation of the serotonin system by endocannabinoid signaling.

Authors:  Samir Haj-Dahmane; Roh-Yu Shen
Journal:  Neuropharmacology       Date:  2011-02-24       Impact factor: 5.250

7.  Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

Authors:  Clinton E Canal
Journal:  Handb Exp Pharmacol       Date:  2018

8.  Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

Authors:  Aimee L McRae-Clark; Nathaniel L Baker; Kevin M Gray; Therese K Killeen; Amanda M Wagner; Kathleen T Brady; C Lindsay DeVane; Jessica Norton
Journal:  Drug Alcohol Depend       Date:  2015-08-25       Impact factor: 4.492

9.  A placebo-controlled trial of buspirone for the treatment of marijuana dependence.

Authors:  Aimee L McRae-Clark; Rickey E Carter; Therese K Killeen; Matthew J Carpenter; Amy E Wahlquist; Stacey A Simpson; Kathleen T Brady
Journal:  Drug Alcohol Depend       Date:  2009-08-21       Impact factor: 4.492

Review 10.  Animal models of serotonergic psychedelics.

Authors:  James B Hanks; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2012-09-24       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.